Q3 2025 EPS Estimates for ResMed Inc. (NYSE:RMD) Boosted by William Blair

ResMed Inc. (NYSE:RMD) – William Blair lifted their Q3 2025 earnings per share estimates for ResMed in a report released on Friday, August 2nd. William Blair analyst M. Kaczor now expects that the medical equipment provider will post earnings of $2.21 per share for the quarter, up from their previous estimate of $2.10. The consensus estimate for ResMed’s current full-year earnings is $8.79 per share. William Blair also issued estimates for ResMed’s Q4 2025 earnings at $2.32 EPS.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.05. ResMed had a net margin of 21.79% and a return on equity of 25.58%. The business had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.22 billion. During the same period in the prior year, the business earned $1.60 earnings per share. The company’s quarterly revenue was up 6.9% compared to the same quarter last year.

Other equities analysts also recently issued research reports about the company. KeyCorp lifted their price objective on ResMed from $238.00 to $251.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a report on Tuesday. Citigroup cut ResMed from a “buy” rating to a “neutral” rating in a report on Monday, June 24th. Royal Bank of Canada lifted their target price on ResMed from $204.00 to $206.00 and gave the company a “sector perform” rating in a research report on Friday, August 2nd. Finally, Oppenheimer cut ResMed from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 25th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, ResMed currently has an average rating of “Moderate Buy” and a consensus price target of $204.70.

ResMed Trading Up 1.5 %

RMD opened at $218.95 on Monday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.04 and a quick ratio of 1.97. The company’s 50 day simple moving average is $203.94 and its two-hundred day simple moving average is $196.95. The firm has a market capitalization of $32.17 billion, a price-to-earnings ratio of 33.63, a price-to-earnings-growth ratio of 1.93 and a beta of 0.66. ResMed has a 1-year low of $132.24 and a 1-year high of $225.68.

ResMed Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 19th. Shareholders of record on Thursday, August 15th will be paid a dividend of $0.53 per share. The ex-dividend date is Thursday, August 15th. This is a positive change from ResMed’s previous quarterly dividend of $0.48. This represents a $2.12 dividend on an annualized basis and a yield of 0.97%. ResMed’s dividend payout ratio is 29.49%.

Insider Transactions at ResMed

In other ResMed news, CFO Brett Sandercock sold 1,000 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $209.81, for a total value of $209,810.00. Following the completion of the transaction, the chief financial officer now owns 91,056 shares in the company, valued at $19,104,459.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other ResMed news, CFO Brett Sandercock sold 1,000 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $209.81, for a total value of $209,810.00. Following the sale, the chief financial officer now owns 91,056 shares of the company’s stock, valued at approximately $19,104,459.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Justin Leong sold 48,000 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $217.07, for a total value of $10,419,360.00. Following the transaction, the insider now directly owns 18,741 shares of the company’s stock, valued at $4,068,108.87. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 79,726 shares of company stock valued at $16,843,287. 1.21% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ResMed

Several institutional investors have recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC acquired a new stake in ResMed in the fourth quarter valued at $27,000. Hall Laurie J Trustee acquired a new stake in ResMed during the first quarter worth approximately $32,000. OFI Invest Asset Management acquired a new position in shares of ResMed in the 2nd quarter valued at $32,000. BOK Financial Private Wealth Inc. purchased a new position in shares of ResMed in the 1st quarter valued at $35,000. Finally, Versant Capital Management Inc raised its stake in ResMed by 196.7% during the 2nd quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 120 shares in the last quarter. 54.98% of the stock is owned by hedge funds and other institutional investors.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.